Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Chief Financial Officer | June 08, 2020 | June 12, 2020 |
| SeaStar Medical Holding CorpICU · Entity 7863 | Chief Financial Officer | April 01, 2025 | April 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date June 08, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 521,250 |
Reported balance
After 2020-06-08 transaction · row 1
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 250,000 · Balance 521,250 F1: These are restricted shares. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024 |
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2030-06-07 | Direct | 100,000 |
Reported balance
After 2020-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-08 · Grant · Acquired 100,000 · Balance 100,000 F2: 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted shares. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024
F2: 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024.
SeaStar Medical Holding Corp
Report date April 01, 2025 · Filed April 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2025-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-01 · Grant · Acquired 15,000 · Balance 15,000 F1: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of ICU common stock.
F2: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2025 Filed Apr 3, 2025 23:33 UTC | SeaStar Medical Holding Corp ICU · Entity 7863 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028747 · marketforms-69089.xml · derivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $0.0001 per share · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025. F2 · derivative.expiration_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025. Read SEC document |
| August 30, 2024 Filed Sep 9, 2024 22:24 UTC | SeaStar Medical Holding Corp ICU · Entity 7863 | GrantCommon Stock, par value $0.0001 per share | 8,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-077008 · marketforms-66986.xml · nonDerivative · entry 2 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,323 F3 · shares: Represents a grant of fully vested shares of the Issuer's common stock. Read SEC document |
| April 18, 2024 Filed Sep 9, 2024 22:24 UTC | SeaStar Medical Holding Corp ICU · Entity 7863 | GrantCommon Stock, par value $0.0001 per share | 2,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-077008 · marketforms-66986.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,223 F1 · shares: Represents a grant of fully vested shares of the Issuer's common stock on a post reverse split basis. The original grant was for 55,556 shares. F2 · shares: On June 7, 2024, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock. This amount represents the number of shares of common stock issued to the Reporting Person as of April 18, 2024 on a post-split basis. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 23:05 UTC | SeaStar Medical Holding Corp ICU · Entity 7863 | GrantCommon Stock, par value $0.0001 per share | 752,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000929638-24-001502 · form4.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,500 F1 · shares: Represents shares of the Issuer's common stock underlying restricted stock units ("RSUs") awarded to the Reporting Person. All shares reported herein will vest, subject to continued service, on the first anniversary of Mr. Green's appointment date. Twenty-five percent (25%) of the shares will vest upon completion of one (1) year of service measured from January 10, 2024, and the remaining seventy-five percent (75%) of the shares will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service over the thirty-six (36)-month period measured from January 10, 2025. Read SEC document |
| April 12, 2024 Filed Sep 9, 2024 22:23 UTC Amendment | SeaStar Medical Holding Corp ICU · Entity 7863 | GrantRestricted Stock Units · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-077007 · marketforms-66983.xml · derivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock, par value $0.0001 per share · 18,000 shares Expires not disclosed F1 · security: On April 16, 2024, a Form 4 (the "Original Report") was filed on behalf of the Reporting Person which inadvertently overstated the number of restricted stock unites ("RSUs") reported in Column 4 and Column 5 of Table I due to an administrative error. This Form 4 amendment is being filed to correct the aggregate number of RSUs issued to the Reporting Person as of the original transaction date from 30,100 RSUs (752,500 pre reverse split) to 18,000 RSUs (450,000 pre reverse split), and to report the grant of such RSUs on Table II, instead of Table I as set forth on the Original Report. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · shares: On June 7, 2024, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock. This amount represents the number of RSUs granted to the Reporting Person as of April 12, 2024 on a post-split basis. F4 · derivative.exercise_date: The RSUs will vest, subject to continued service, on the first anniversary of Mr. Green's appointment date. Twenty-five percent (25%) of the RSUs will vest upon completion of one (1) year of service measured from January 10, 2024, and the remaining seventy-five percent (75%) of the RSUs will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service over the thirty-six (36)-month period measured from January 10, 2025. F4 · derivative.expiration_date: The RSUs will vest, subject to continued service, on the first anniversary of Mr. Green's appointment date. Twenty-five percent (25%) of the RSUs will vest upon completion of one (1) year of service measured from January 10, 2024, and the remaining seventy-five percent (75%) of the RSUs will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service over the thirty-six (36)-month period measured from January 10, 2025. F3 · derivative.underlying_shares: On June 7, 2024, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock. This amount represents the number of RSUs granted to the Reporting Person as of April 12, 2024 on a post-split basis. F3 · balance_after: On June 7, 2024, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock. This amount represents the number of RSUs granted to the Reporting Person as of April 12, 2024 on a post-split basis. Read SEC document |
| June 08, 2020 Filed Jun 12, 2020 17:46 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 100,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001654954-20-006585 · section16.xml · derivative · entry 2 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-07 F2 · derivative.exercise_date: 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024. Read SEC document |
| June 08, 2020 Filed Jun 12, 2020 17:46 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-20-006585 · section16.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,250 F1 · price: These are restricted shares. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024 Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 16:45 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 1,500 | $1.04 | $1,552.50 |
DisclosureSEC source: 0001654954-19-001667 · section16.xml · nonDerivative · entry 2 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,250 Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 16:45 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 3,500 | $1.04 | $3,636.50 |
DisclosureSEC source: 0001654954-19-001667 · section16.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,750 Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 16:00 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | SaleCommon Stock | 3,330 | $0.81 | $2,710.95 |
DisclosureSEC source: 0001213900-18-017852 · ownership.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,250 F1 · balance_after: Aggregate amount indicated reflects 20-for-1 reverse split and includes post-split restricted shares previously issued. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 19:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 262,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-014537 · ownership.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,580 F1 · price: These are restricted shares which vest on October 24, 2028, subject to earlier vesting in certain situations. F2 · balance_after: Aggregate amount indicated reflects 20-for-1 reverse split and includes additional 3,750 post-split restricted shares previously issued. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 16:38 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrants · Derivative | 66,600 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-18-002656 · f4030618green_aytubio.xml · derivative · entry 2 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,600 Underlying: Common Stock · 66,600 shares Expires 2023-03-06 F2 · price: Warrants were issued as part of units with the shares of common stock. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 16:38 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 66,600 | $0.45 | $29,970.00 |
DisclosureSEC source: 0001213900-18-002656 · f4030618green_aytubio.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,600 F1 · balance_after: Includes 75,000 restricted shares. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:50 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-000085 · f4010218green_aytubioscience.xml · nonDerivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · shares: These are restricted shares that vest on January 2, 2028, subject to earlier vesting in certain situations. F1 · price: These are restricted shares that vest on January 2, 2028, subject to earlier vesting in certain situations. F1 · balance_after: These are restricted shares that vest on January 2, 2028, subject to earlier vesting in certain situations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.